



OPEN ACCESS

EDITED BY

Carlos Alberto Moreira-Filho,
University of São Paulo, Brazil

REVIEWED BY

Ariadna Cruz-Córdova,
Federico Gómez Children's Hospital, Mexico
Victor Meza Carmen,
Michoacana University of San Nicolás de
Hidalgo, Mexico

*CORRESPONDENCE

Xiaoning Liu

✉ liuxn@lzu.edu.cn

Duochun Wang

✉ wangduochun@icdc.cn

RECEIVED 21 October 2023

ACCEPTED 21 December 2023

PUBLISHED 10 January 2024

CITATION

Li K, Yu K, Huang Z, Liu X, Mei L, Ren X, Bai X,
Gao H, Sun Z, Liu X and Wang D (2024)
Stenotrophomonas maltophilia complex:
insights into evolutionary relationships, global
distribution and pathogenicity.
Front. Cell. Infect. Microbiol. 13:1325379.
doi: 10.3389/fcimb.2023.1325379

COPYRIGHT

© 2024 Li, Yu, Huang, Liu, Mei, Ren, Bai, Gao,
Sun, Liu and Wang. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Stenotrophomonas maltophilia complex: insights into evolutionary relationships, global distribution and pathogenicity

Kun Li^{1,2}, Keyi Yu², Zhenzhou Huang³, Xiao Liu², Li Mei⁴,
Xiaodong Ren^{1,2}, Xuemei Bai², He Gao², Zhiwen Sun²,
Xiaoning Liu^{1*} and Duochun Wang^{2*}

¹School of Public Health, Lanzhou University, Lanzhou, China, ²National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China,

³Microbiology Laboratory, Hangzhou Center for Disease Control and Prevention, Hangzhou, China,

⁴National Pathogen Resource Center, Chinese Center for Disease Control and Prevention, Beijing, China

Introduction: *Stenotrophomonas maltophilia* complex (Smc) comprises opportunistic Gram-negative bacilli responsible for various nosocomial infections. Limited data exists concerning its evolutionary lineage, global prevalence and pathogenicity.

Methods: We conducted an extensive genomic analysis on 734 Smc genomes, of which 90 were newly sequenced and isolated from different patients. The species composition and evolutionary relationships of Smc were examined using core protein sequence analysis. Pathogenicity evaluation was used by assays for swimming motility, biofilm formation and identification of virulence factors. The broth microdilution method was used to evaluate the drug resistance spectrum of clinical isolates.

Results: Phylogenetic analyses delineated 24 species-level clades, dominated by *S. maltophilia* (42.8%), *S. seipilia* (13.6%) and *S. geniculata* (9.9%). Geographically, strains were primarily distributed in Europe (34.2%), Asia (33.7%) and North America (24.0%), with intricate global distribution patterns. Meanwhile, 154 virulence-associated genes and 46 antimicrobial resistance genes within Smc were identified. These genes encoded span various functions, including motility, adherence, toxin, RND antibiotic efflux pumps, beta-lactamases and aminoglycoside-modifying enzymes. Moreover, significant variations were indicated in swimming motility and biofilm-forming capability across the different species, with *S. seipilia* exhibiting superior levels of both traits. Additionally, no statistically significant discrepancy was detected among Smc species to other antibiotics, despite the fact that all *S. geniculata* isolates were resistant to Ceftazidime and much higher than other species.

Conclusion: Our findings indicate the need to pay increased attention to other mainstream species of Smc besides *S. maltophilia* in order to better manage Smc-related infections and tailor effective treatment strategies.

KEYWORDS

Stenotrophomonas maltophilia complex, evolution, global distribution, pathogenicity, swimming motility, biofilm

Introduction

The genus *Stenotrophomonas* comprises aerobic Gram-negative bacteria and belongs to the family *Lyobacteraceae*. It exhibits high diversity and metabolic versatility and can be found ubiquitously in the environment, including water, soil, plant rhizospheres and animals (Patil et al., 2016; Brooke, 2021). Currently, the genus *Stenotrophomonas* consists of 25 validated species, as documented by the List of Prokaryotic Names with Standing in Nomenclature (<https://lpsn.dsmz.de/>). Among them, *Stenotrophomonas maltophilia* stands as the first identified and clinically most significant species (Palleroni and Bradbury, 1993). Thorough taxonomic and phylogenomic investigations have demonstrated that *S. maltophilia* includes multiple cryptic species, giving rise to the *Stenotrophomonas maltophilia* complex (Smc) and a distinction that eludes conventional classification methods (Ochoa-Sánchez and Vinuesa, 2017; Kumar et al., 2020; Singh et al., 2023). This assemblage involves previously documented taxa, including *Pseudomonas hibiscicola*, *Pseudomonas beteli*, *S. africana*, *S. geniculata*, *S. maltophilia*, *S. pavanii* and *S. seipilia*, with *S. maltophilia* being the prevalent species (Rhee et al., 2013; Kumar et al., 2020; Gautam et al., 2021).

S. maltophilia constitutes an emerging opportunistic pathogen that is accountable for a wide range of nosocomial infections, including respiratory infections, bacteremia, skin and soft tissue infections, eye infections and infections connected to medical implants (Brooke, 2021). A pivotal virulence factor contributing to its pathogenicity is its capacity for attachment to both inanimate surfaces and tissues of the host, resulting in the formation of biofilm communities that possess innate resistance to antibiotics and immune responses (Pompilio et al., 2008; Pompilio et al., 2020). Moreover, it has been observed that *S. maltophilia* has the ability to establish colonization in the respiratory tract of individuals with cystic fibrosis, hence elevating the risk of pulmonary exacerbations and mortality (Waters et al., 2011; Waters et al., 2013). Furthermore, the bacterium's inherent ability to resist widely utilized antimicrobial agents, including cephalosporins, carbapenems, aminoglycosides, and macrolides, stems from low membrane permeability, active antibiotic efflux pumps, and antibiotic-modifying enzymes (Wang et al., 2018; Gil-Gil et al., 2020). This resistance poses a substantial threat to patients receiving treatment, particularly those with compromised immune systems (Zhao et al., 2018; Gil-Gil et al., 2020). Additionally, *S. maltophilia* can play a significant role in microbiological co-infections. For instance, *S. maltophilia* has been found to provide significant levels of protection against antibiotics for *Pseudomonas aeruginosa*, which would otherwise be susceptible to them (Bottery et al., 2022; Lee et al., 2022) and interfere with the isolation cultures and drug sensitivity tests of *Mycobacterium tuberculosis*, potentially leading to alterations in treatment plans and an escalation in the burden of the disease (Li et al., 2023).

Prior research provides evidence for the presence of various species inside the Smc that are connected with human infections (Patil et al., 2018; Gautam et al., 2021). However, there are large knowledge gaps in our understanding of clinically and environmentally relevant aspects of these closely related species,

such as the prevalence or proportion, the virulence factors along with the antimicrobial-resistance characteristics of each species of Smc. The wealth of genome sequences available in public databases offers a valuable resource to bridge these knowledge gaps.

In this study, we analyzed 90 newly sequenced clinical isolates from diverse regions of China together with genomes with strict quality control from public databases. We reconstructed the phylogenetic relationship of the genus *Stenotrophomonas* and updated the species composition of Smc. Furthermore, we explore the global population distribution structure of these species, investigate the sources of isolates, and analyze the presence of virulence and resistance genes. Additionally, the differences in biofilm formation ability, swimming ability and drug resistance phenotype among the 90 clinically derived Smc that we have newly sequenced were further evaluated. This study enhances the comprehension of the population structure and worldwide distribution of different species within the Smc, and provides the basis for gaining further insights into the species-specific clinical characteristics, potential pathogenicity, and resistance spectrum of the Smc.

Materials and methods

Bacterial strains and DNA isolation

All 90 strains in this study were routinely isolated from clinical specimens of different patients in China between 2019 and 2023 (Supplementary Table S1). The source from which most isolates were obtained was human sputum, followed by trachea tube, suggesting that most strains isolate from respiratory. All strains were identified as *S. maltophilia* by MALDI-TOF MS and DNA was extracted using the Genomic DNA Extraction Kit (Tiangen biochemical technology Co. Ltd., Beijing, China).

Whole-genome data collection and sequencing

A total of 758 *S. maltophilia* genomes were analyzed in this study. Among them, 90 clinical strains were newly sequenced (Supplementary Table S1). Another 668 uncontaminated genomes labeled "*Stenotrophomonas maltophilia*" with less than 200 contigs were screened and included from NCBI (<https://www.ncbi.nlm.nih.gov/datasets/genome/>) as of March 2023 (Supplementary Table S2).

Genomes were sequenced using the Illumina HiSeq 2000 platform. The raw sequence data was evaluated by FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>), and the low-quality reads were filtered. The reads data was assembled into contigs using SOAP *de novo* v2.04 (Li et al., 2019). QUAST v5.0.2 (Gurevich et al., 2013) software was applied to evaluate the genome assembly. The genome size, number of coding sequences (CDSs), and GC content were estimated using Prokka v1.13.3 (Seemann, 2014).

Calculation of average nucleotide identity and phylogenetic tree construction

FastANI (Jain et al., 2018) was employed to calculate the pairwise average nucleotide identity (ANI). The similarity matrix was imported into R and plotted as a heatmap of all strains. The strains belonged to the same species when the ANI value was above 95%. The genomes that could not be assigned to a known species were compared against all type strain genomes available in the TYGS (Type (Strain) Genome Server, <https://tygs.dsmz.de/>) database via the MASH algorithm to determine closely related type strains.

Phylogenetic analysis of the genus *Stenotrophomonas* follows the previously described method (Huang et al., 2022). Ten representative genomes were selected to cover the overall genetic distance of each species for those species with more than 10 available sequenced genomes, and all the genomes for the species with less than 10 publicly available sequences were adopted. Finally, a total of 190 strains were included, and the non-redundant homologous gene set was computed by CD-HIT (Fu et al., 2012). Next, BLASTp was used to search the homologous proteins in the nonredundant homologous protein set of each strain with a cutoff value of $\geq 90\%$ sequence identity and $\geq 60\%$ length coverage. Each single-copy core protein sequence was aligned separately using ClustalW2 and then merged. Iqtree v1.6.11 (Minh et al., 2020) was used to construct the phylogenetic trees by the maximum-likelihood method based on all these core SNPs (bootstrap replications, 1000). The visualization and beautification of the phylogenetic tree were accomplished by the tvBOT online tool (<https://www.chiplot.online/tvbot.html>) (Xie et al., 2023).

Identification of virulence-associated genes and antibiotic resistance genes

Nucleotide sequences predicted by Prokka v1.13.3 (Seemann, 2014) and produce *.gff output files were used for the following identification of core genes by Roray v2.3.12 (Page et al., 2015), with default parameters. To identify the virulence-associated genes, the protein sequences of all genomes were aligned using BLASTp with a relatively relaxed cutoff (60% identity, 60% length coverage) and an E value of $1e-5$ against the data set from the VFDB (Liu et al., 2022). The antibiotic resistance genes (ARGs) were predicted using Resistance Gene Identifier (RGI) v6.0.2 with cutoffs of 75% identity and 80% length coverage against the data set from the Comprehensive Antibiotic Resistance Database (CARD, <https://card.mcmaster.ca/>) (Alcock et al., 2023).

Swimming motility assay

Logarithmically grown bacterial culture was adjusted to an optical density at 600 nm (OD_{600}) of 0.4–0.5, and an aliquot (2 μ L) of the culture was transferred into the LB semisoft

(0.15% agar) agar motility plates, followed by incubation at 37°C for 22–24 h. Three parallel controls were set up, and the bacterial expansion zone diameters (millimeters) were measured.

Biofilm formation assay

The crystal violet (CV) staining method was used to quantify the ability of each isolate to form biofilm as previously described (Isom et al., 2022). Bacterial cultures of strains were grown overnight in LB medium, and 2 mL was next inoculated into an individual test sterile polystyrene tube (Falcon, Coning; NY, USA) at a 1:50 dilution. Incubation was at 37 °C for 24 h without shaking, under an aerobic atmosphere, and the OD_{600} of each bacterial culture was measured. Then, non-adherent bacteria were removed by washing three times with sterile water carefully, and biofilm samples were fixed for 30 min at 60°C, dyed for 30 min with 0.1% CV, followed by careful rinsing with water to remove excess dyes, and solubilization of the crystal violet using dimethylsulfoxide (DMSO) for 1 h. Finally, the OD_{570} was measured, and the OD_{570}/OD_{600} ratio was used to represent the biofilm formation ability.

Antibiotic susceptibility test

A total of 90 Smc isolates were tested for antimicrobial susceptibility. Minimum inhibitory concentrations (MICs) of 15 antimicrobial agents (Levofloxacin (LVX), Trimethoprim/Sulfamethoxazole (SXT), Minocycline (MH), Ceftazidime (CAZ), Amikacin (AN), Ampicillin/Sulbactam (SAM), Aztreonam (ATM), Cefepime (FEP), Ceftriaxone (CRO), Ciprofloxacin (CIP), Gentamicin (GM), Imipenem (IPM), Ertapenem (ETP), Piperacillin/Tazobactam (TZP), and Tobramycin (NN)) were detected by the broth microdilution method, and the resistance was defined using the Clinical and Laboratory Standards Institute (CLSI) criteria (Clinical Laboratory Standards Institute, 2023). *Pseudomonas aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922 were used as control strains.

Statistical analysis

SPSS 26.0 (IBM Corp., Armonk, NY, USA) was used to conduct the statistical analysis. For categorical variables, the χ^2 test or Fisher's exact test was used to determine statistical significance. $P < 0.01$ was considered to indicate statistical significance.

Data availability

The genome sequences of the 90 clinical Smc strains sequenced in this study have been deposited at GenBank/DBJ/ENA under the BioProject ID no. PRJNA1019301.

Results


Phylogenetic reconstruction of Smc and its composition of species

The 758 genomes were compared with type strains of the *Stenotrophomonas* genus by ANI calculations, and a total of 32 species-level clades were identified (Figure 1A). Among them, in addition to the 637 genomes assigned to 11 well-defined species, 121 genomes remained unassigned to any known species. Subsequently, the 121 strains were compared to the TYGS database, resulting in their identification as *Stenotrophomonas* spp., and could be further assigned to 21 novel *Stenotrophomonas* species named Genospecies 1 through Genospecies 21 (Supplementary Table S2). It is worth noting that out of the 734 strains classified as “*S. maltophilia*”, only 314 (41.4%) were confirmed to be *S. maltophilia*. The majority of the remaining strains belonged to different species within the genus *Stenotrophomonas*.

The determination of phylogenetic connections among *Stenotrophomonas* spp. was based on the analysis of core protein sequences (Figure 1B), and the resulting phylogenetic tree revealed 24 species-level clades of Smc. The branches of each species of Smc are characterized by their short and compact arrangement, indicating a close relationship. Consequently, a total of 734 Smc genomes were incorporated into the subsequent analysis, the most prevalent species were *S. maltophilia* ($n = 314$, 42.8%), *S. seipilia* ($n = 100$, 13.6%), *S. geniculata* ($n = 73$, 9.9%), *S. muris* ($n = 68$, 9.3%), and Genospecies 1 ($n = 31$, 4.2%).

Population structure and global distribution of Smc

The analysis incorporated 734 strains from 39 different countries across 6 continents, with the exclusion of 16 isolates lacking information regarding their geographic origin (Figure 2A).






FIGURE 2 Global distribution of species and their composition by isolation source in Smc. (A) Geographic distribution of the 734 *S. maltophilia* complex strains. The map is color-coded by country to indicate the number of strains. (B) Barplot shows the number of strains per species colored by isolation source for the entire strain collection.

These strains were predominantly obtained from China ($n = 201$, 27.4%), the United States ($n = 174$, 23.7%), Italy ($n = 90$, 12.3%), Germany ($n = 60$, 8.2%), and Spain ($n = 28$, 3.8%). The majority of strains are geographically spread over Europe ($n = 251$, 34.2%), Asia ($n = 247$, 33.7%) and North America ($n = 176$, 24.0%). Subsequently, smaller proportions of strains are found in Africa ($n = 27$, 3.6%), South America ($n = 10$, 1.3%) and Oceania ($n = 5$, 0.6%) is the least.

Given the disparity in the distribution of strains between continents, our study concentrated specifically on Europe, Asia and North America. These three continents were chosen due to their more abundant number of strains and species composition. In Europe, the prevalence of *S. maltophilia* was significantly higher (51.8%, $P < 0.005$) compared to the relatively lower occurrence of *S.*

geniculata (4.0%, $P < 0.005$). *S. muris* strains in North America were significantly greater at 14.8% ($P < 0.01$). However, *S. sepiilia* strains in North America were rather low, accounting for only 2.3% ($P < 0.001$). In contrast, higher proportions of these strains were found on the other two continents (Asia (19.0%), Europe (14.3%)). Additionally, *S. maltophilia* exhibits dominance as the prevailing species in South America and Oceania, while *S. sepiilia* strains account for the highest proportion in Africa.

In terms of sample sources of Smc, a majority of the strains ($n = 471$, 64.2%) were obtained from clinical sources. The isolation source was categorized into five distinct groups (Figure 2B). The predominant isolates from the human respiratory tract were strains of Genospecies 19 (100%), Genospecies 2 (57.1%) and *S. maltophilia* (52.5%). Genospecies 4 (50.0%), Genospecies 5

(50.0%) and Genospecies 3 (40.0%) contained significantly more human-invasive strains compared with all other isolation sources. The prevalence of human-non-invasive origin strains was found to be significantly higher in Genospecies 14 (100%), Genospecies 7 (61.5%) and *S. muris* (20.6%). Additionally, environmental strains were more common in Genospecies 18 (100%), Genospecies 20 (100%), Genospecies 21 (100%) and Genospecies 9 (66.7%).

Distribution pattern of virulence-associated genes and ARGs in Smc

According to the annotations and predictions made by the VFDB database, 17 virulence factor classes, involving 154 virulence-associated genes, were obtained from 734 Smc genomes (Table 1; Figure 3), each genome contains an average of 34 virulence genes. Belonging to 7 virulence factor classes (flagella, pili, LPS, capsule, protease, Hsp60 and EF-Tu) including 25 genes were present in almost all of the Smc genomes. In addition, there are variations in the distribution of certain genes among the species of the Smc. Specifically, the *cheA* and *manC* genes were exclusively found in *S. maltophilia*, where they play a crucial role in flagella formation and adhesion, respectively. Moreover, we found genes associated with type VI secretion system (T6SS) in numerous species of the complex, including Genospecies 7 (100%), Genospecies 12 (100%), Genospecies 3 (90%), *P. hibiscicola* (35.7%), Genospecies 1 (35.5%) and *S. seipilia* (33.0%). The presence of the *gtrB* gene, which plays a role in the modification of lipopolysaccharide (LPS) O-antigen, was merely seen in *S. muris*. The *tpaA* gene, encoding Type IV pili, was found solely in *S. seipilia*. Similarly, the *xcpS* gene, encoding the general secretion pathway protein F, was only found in Genospecies 11. It is worth noting that a higher percentage of *S. seipilia* strains (22%) lack the *kata* gene, which is a catalase enzyme that plays a role in increasing persistence levels in response to hydrogen peroxide disinfectants and is found in nearly all other genomes.

A total of 46 ARGs, referring to 7 antimicrobial classes of drugs, were identified against the CARD (Figure 3). Almost all genomes carry genes encoding resistance-nodulation-cell division (RND) antibiotic efflux pump, beta-lactamase and aminoglycoside phosphotransferase (APH), indicating the principal resistance mechanism of Smc. The prevalence of genes producing aminoglycoside acetyltransferase (AAC) was found to be approximately 37.1%. These genes were predominantly observed in strains of *S. maltophilia*, *S. pavanii*, and *S. speilia*. Another aminoglycoside-modifying enzyme, aminoglycoside nucleotidyltransferase (ANT), was exclusively encoded in *S. maltophilia*, *S. muris*, Genospecies 1 and *P. hibiscicola*. In addition, all strains of *P. hibiscicola*, Genospecies 1, Genospecies 4, and Genospecies 7 did not encode smeABC (a multidrug resistance RND-type efflux pump that confers resistance to aminoglycosides, beta-lactams, and fluoroquinolones) or smeRS (a two-component regulatory system for smeABC). The sulfonamide-resistance-conferring *sul1* or *sul2* were found in 26 strains (3.6%), mostly occurring in clinical strains, which suggests a

TABLE 1 The classification of virulence related factors of Smc.

VF-class	Virulence genes	Productions	Functions
Flagella	<i>cheA, cheB, cheD, cheR, cheV, cheV3, cheW, cheY, fimD, fimE, flaA, flaB, flaD, fleQ, flgD, flgE, flgG, flgI, flhA, flhF, fliA, fliC, fliG, fliI, fliM, fliN, fliP, flmH, flrA, motB, tlpA, tlpB, tsr</i>	Chemotaxis protein, chemotaxis methyltransferase, flagellin, transcriptional regulator, flagellar protein, flagellar biosynthesis sigma factor, flagellar protein, type I fimbriae, flagellum-specific ATP synthase, short chain dehydrogenase, FleQ protein, membrane-bound chemoreceptor sensing pH and autoinducer-2	Motility, adherence to surfaces, colonization or invasion, maintenance at the infection site, damage to host
Pili	<i>flpF, mshC, mshE, pilB, mtrD, pila, pilC, pilE, pilG, pilH, pilI, pilM, pilR, pilT, pilU, pilV, pilX, tapA, tapB, tapT, tapU, tcpI, tppA, tppF</i>	Traffic ATPase, MSHA pili minor prepilin protein, MSHA biogenesis protein, trifunctional thioredoxin, resistance system protein, type 4 fimbrial precursor, type IV pilus major pilin, twitching motility protein, twitching ATPase, negative regulator of the major pilin, type IV pilus pseudopilin	Motility, adherence to surfaces, adaptation, nutrient acquisition, biofilm formation, sense initial contact with surfaces, damage to host
T2SS	<i>exeG, lspF, lspG, xcpR, xcpS, xcpT</i>	General secretion pathway protein G, general secretion pathway protein F, general secretion pathway protein E	Damage to host, route of protein export across the cytoplasmic membrane,
T3SS	<i>bscN, invG, spaQ, yopO/yopK</i>	ATP synthase, secretin, minor export apparatus protein, effector YopO	Transport virulence factor, protein secretion,
T4SS	<i>CBU_1566, CBU_1594, lpg2936, ptlH, virB10, virB11, virB4, virB9</i>	Translocated effector, protein ATPase, channel protein	Transfer of information between cells, Spread of bacterial resistance
T6SS	<i>clpV1, hcp1, hsiB1/vipA/mglA, hsiC1/vipB/mglB, icmF1/tssM1, rhs/PAAR, tagT, tli1, vasH/clpV, vgrG1b</i>	AAA+ family ATPase, HcpA-like protein, tubule-forming protein, PAAR family protein, protein TagT, immunity protein, transcriptional regulator,	Effector protein transfer, protein secretion, virulence, chaperone
Toxin	<i>chuU, cylB, ddhA, dhbC, dhbE, entE, entF, fdeC, fepA, fepB, hlyB, rtxA, rtxB, rtxE, sodB</i>	Heme permease protein, ABC-type transporter, structural toxin protein, RTX toxin transporter, superoxide dismutase, hemolysin B, adhesin FdeC, enterobactin synthase, isochorismate synthase,	Bacillibactin, enterobactin, adherence, damage to host, projection against hosts

(Continued)

TABLE 1 Continued

VF-class	Virulence genes	Productions	Functions
LPS	<i>bplA, bplB, bplC, gmd, gtrB, kdsA, manB, per, wbtH, wbtL</i>	Oxidoreductase, acetyltransferase lipopolysaccharide biosynthesis protein, GDP-mannose 4,6-dehydratase, bactoprenol glucosyl transferase, 2-dehydro-3-deoxyphosphoconate aldolase, phosphomannutase perosamine synthetase, asparagine synthase, glucose-1-phosphate thymidyltransferase	Adherence, immune evasion, endotoxin, Toll-like receptor
Anti-resistance	<i>acrB, adeG</i>	Acriflavine resistance protein B, cation/multidrug efflux pump	Anti-resistance
Biosynthesis	<i>carA, carB</i>	Carbamoyl phosphate synthase	Pyrimidine biosynthesis
Capsule	<i>cps4I, cpsJ, gmd, gnd, hasB, kpsF, manC, rpe, ugd</i>	capsular polysaccharide biosynthesis protein, ATP-binding protein, phosphogluconate dehydrogenase, pyrophosphorylase, UDP-glucose dehydrogenase	Adherence
Catalase	<i>kata</i>	Catalase	Protection against host defenses
IlpA	<i>IlpA</i>	Immunogenic lipoprotein A	Endotoxin
Iron uptake	<i>irtB, iutA, mbtH-like</i>	Iron-regulated transporter IrtB, ferripyoverdine receptor FpvA, ferric aerobactin receptor IutA	Transcription activation, signaling receptor, transport
LOS	<i>kdsA, lpxB</i>	2-dehydro-3-deoxyphosphoconate aldolase, lipid-A-disaccharide synthase	Endotoxin
Protease	<i>iroN, clpC, clpP, icl, iroB, mucD, pgaC, phoP, mgtB, mgtC</i>	ATP-dependent Clp protease proteolytic, isocitratase, glucosyltransferase, serine protease	Adhesion and invasion, fibrinogen cleavage
Hsp60	<i>htpB</i>	60K heat shock protein HtpB	Mediate complement-independent attachment to the host cells
Biofilm	<i>Bap, bfmR</i>	Biofilm-associated protein, biofilm-controlling response regulator	Biofilm formation
EF-Tu	<i>tufA</i>	Elongation factor Tu	Protein synthesis

relatively low prevalence of trimethoprim/sulfamethoxazole-resistant strains in our collection, which is the recommended first-line agent for the treatment of *S. maltophilia* infection.

Swimming motility and biofilm formation ability

We conducted an assessment of the swimming motility and biofilm forming capabilities of 90 clinical strains obtained from Smc, encompassing 13 distinct species. The findings indicated significant variations in swimming motility across the different species. *S. seipilia* exhibits the highest level of swimming proficiency, followed by *S. pavanii*, whereas Genospecies 2 displays the lowest swimming motility (Figure 4A). Meanwhile, these species have been identified with varying degrees of biofilm-forming capability. *S. maltophilia* and *S. seipilia* in particular have shown stronger biofilm formation activity, followed by Genospecies 2 and *S. africana*, whereas Genospecies 3 was classified as the weakest biofilm producer (Figure 4B).

Antibiotic resistance phenotypic of Smc

A resistance phenotypic test was performed on 15 antibiotics against Smc (Supplementary Table S3). Our analyses focused on the resistance of four therapeutic drugs against *S. maltophilia* infections (Table 2). From all of the isolates, 44 were susceptible to the four antibiotics tested, whereas three strains, SMYL 1 (*S. geniculata*), SMYL 8 (Genospecies 1), SMYL 55 (*S. maltophilia*), were resistant or intermediary to three antibiotics. Surprisingly, all 14 strains of *S. geniculata* revealed resistance to Cefazidime and exhibited significantly higher than other species ($P < 0.001$, Fisher's exact test for $n < 5$). No statistically significant variation was observed between species in terms of resistance to the remaining three antibiotics.

Discussion

In this study, we constructed an extensive genome dataset containing 734 strains by combining 90 newly sequenced genomes of Smc. The results of phylogenetic analysis revealed that 24 species consist of Smc, and the topological structure coincided with previous researches (Patil et al., 2018; Gröschel et al., 2020). We incorporate the introduction of *S. muris*, a recently described species, into the species composition of the Smc. Based on the number of strains, *S. maltophilia* remained the dominant species within Smc (42.8%). Moreover, it is noteworthy that *S. seipilia*, *S. geniculata*, and *S. muris* have emerged as the dominant emerging strains in the Smc. Importantly, little is known about the pathogenicity of these species in humans, warranting further investigation.




FIGURE 4 Determination of swimming motility and biofilm formation ability. **(A)** The swimming motility on LB (0.15% agar) measurement results of 90 clinical strains. Each image presented in the study depicts the expansion zone diameters of a single strain that is most representative of the average for its respective species. **(B)** Biofilm formation ability assay (crystal violet staining). Box plot shows the measurement results of each strain.

correlation between the organism’s ability to develop biofilms and its level of pathogenicity (Pompilio et al., 2020). It is remarkable that *S. seipilia* has an unimaginable ability for swimming motility and biofilm formation. Its type strain was isolated from blood cultures of hospitalized patients (Gautam et al., 2021), indicating its underestimated pathogenicity. According to the prevalence

analysis, *S. seipilia* has become the dominant strain in Smc, which deserves more attention.

There is a consensus that *S. maltophilia* exhibits resistance to a majority of antibiotics, leaving only a limited number of clinically effective drugs available to combat this organism (Gil-Gil et al., 2020; Brooke, 2021). Our study of clinical Smc strains found that

TABLE 2 Four clinical antibiotic susceptibilities of 90 Smc isolates.

Antibiotic ^a	MIC (µg/mL) Range	Susceptibility (%)			Non-susceptible species ^b (n)
		S	I	R	
CAZ	≤ 1 to ≥ 32	50 (55.6)	7 (7.7)	33(36.7)	<i>S. mal</i> (17), <i>S. gen</i> (14), <i>S. sep</i> (2), G1 (2), <i>S. afr</i> (1), <i>S. muris</i> (1), G 2 (1), G 3 (1), G 7 (1)
LEV	≤ 1 to ≥ 8	79 (87.8)	5 (5.5)	6 (6.7)	<i>S. mal</i> (3), <i>S. gen</i> (2), <i>S. mur</i> (2) <i>S. sep</i> (2), <i>S. pav</i> (1), <i>P. hib</i> (1), G 1 (1)
MH	≤ 1 to 8	87 (96.7)	3 (3.3)	0	<i>S. mal</i> (1), <i>S. gen</i> (1), G 1 (1)
SXT	≤ 1/19 to ≥ 4/76	88 (97.8)	–	2 (2.2)	<i>S. mal</i> (1), <i>S. mur</i> (1)

^aAntibiotic: CAZ, Ceftazidime; LVX, Levofloxacin; SXT, Trimethoprim/Sulfamethoxazole; MH, Minocycline.

^bSpecies: *S. gen*, *S. geniculata*; *S. mal*, *S. maltophilia*; *S. sep*, *S. seipilia*; *S. afr*, *S. africana*; *S. mur*, *S. muris*; *S. pav*, *S.pavanii*; *P. hib*, *P. hibiscicola*; G 1, Genospecies 1; G 2, Genospecies 2; G 3, Genospecies 3; G 7, Genospecies 7.

S, susceptible; R, resistance; I, intermediate.

these strains exhibited a high sensitivity rate to trimethoprim/sulfamethoxazole and minocycline. This finding is similar to the global overall susceptibility reported in the recent SENTRY study (Gales et al., 2019). However, all 14 *S. geniculata* strains were found to be resistant to Cefazidime, and the resistance rate was significantly higher than other species in Smc, but we did not find that *S. geniculata* has a special genotype for the prediction of resistance genes. This may be an effect due to their complex resistance mechanism, the drug resistance phenotype and genotype of Smc are not always consistent (Wang et al., 2021), and the antibiotic efflux pump system may play an important role (Sánchez and Martínez, 2015).

As above stated, this study provides a comprehensive overview of the population diversity, evolution, and pathogenic characteristics of the understudied pathogen Smc. The 24 species-level clades of SMC vary in geographical distribution and pathogenic potential. Our research indicates that *S. geniculata* and *S. seipilia* display worrying phenotypic characteristics related to drug resistance and virulence, respectively, but currently we know very little about these clinical mainstream species of Smc. To better address infections caused by Smc, further studies are required to assess and compare species-specific characteristics related to epidemiology, disease spectrum, resistance, and virulence of species of Smc. Likewise, research is also needed to set out to identify unambiguous molecular targets that could reliably distinguish between these pathogens at the species level. Proper species delimitation is essential for uncovering species-specific phenotypic characteristics and enhancing our understanding of this complex pathogen.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

KL: Data curation, Formal analysis, Investigation, Visualization, Writing – original draft, Methodology, Validation. KY: Formal analysis, Methodology, Validation, Writing – review & editing. ZH: Formal analysis, Methodology, Software, Writing – review & editing. XL: Data curation, Methodology, Writing – review & editing. LM: Data curation, Methodology, Writing – review &

editing. XR: Data curation, Investigation, Validation, Writing – review & editing. XB: Methodology, Validation, Writing – review & editing. HG: Investigation, Methodology, Validation, Writing – review & editing. ZS: Data curation, Writing – review & editing. XNL: Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – review & editing. DW: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Science and Technology Infrastructure of China (NPRC-32), the establishment of a national *Shewanella* standard strain (TS202303), the construction of protein fingerprints of rare pathogen (KFYJ-2022-039) and the Operation of Public Health Emergency Response Mechanisms-Infectious Disease Control and Prevention (102393220020020000029).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1325379/full#supplementary-material>

References

- Adamek, M., Linke, B., and Schwartz, T. (2014). Virulence genes in clinical and environmental *Stenotrophomonas maltophilia* isolates: A genome sequencing and gene expression approach. *Microb. Pathog.* 67–68, 20–30. doi: 10.1016/j.micpath.2014.02.001
- Ageorges, V., Monteiro, R., Leroy, S., Burgess, C. M., Pizza, M., Chaucheyras-Durand, F., et al. (2020). Molecular determinants of surface colonisation in diarrhoeagenic *Escherichia coli* (DEC): from bacterial adhesion to biofilm formation. *FEMS Microbiol. Rev.* 44, 314–350. doi: 10.1093/femsre/fuaa008
- Alcock, B. P., Huynh, W., Chalil, R., Smith, K. W., Raphenya, A. R., Wlodarski, M. A., et al. (2023). CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database. *Nucleic Acids Res.* 51, D690–D699. doi: 10.1093/nar/gkac920

- Bottery, M. J., Matthews, J. L., Wood, A. J., Johansen, H. K., Pitchford, J. W., and Friman, V.-P. (2022). Inter-species interactions alter antibiotic efficacy in bacterial communities. *ISME J.* 16, 812–821. doi: 10.1038/s41396-021-01130-6
- Brooke, J. S. (2021). Advances in the microbiology of *Stenotrophomonas maltophilia*. *Clin. Microbiol. Rev.* 34, e00030–e00019. doi: 10.1128/CMR.00030-19
- Chaban, B., Hughes, H. V., and Beeby, M. (2015). The flagellum in bacterial pathogens: For motility and a whole lot more. *Semin. Cell Dev. Biol.* 46, 91–103. doi: 10.1016/j.semdb.2015.10.032
- Chen, L., Zou, Y., She, P., and Wu, Y. (2015). Composition, function, and regulation of T6SS in *Pseudomonas aeruginosa*. *Microbiol. Res.* 172, 19–25. doi: 10.1016/j.micres.2015.01.004
- Clinical and Laboratory Standards Institute (2023). *Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edn. [EB/OL], 33rd edition* (Wayne, PA: Clinical and Laboratory Standards Institute). Available online at: <https://clsi.org/standards/products/microbiology/documents/m100/>.
- Fast, D., Kostiuk, B., Foley, E., and Pukatzki, S. (2018). Commensal pathogen competition impacts host viability. *Proc. Natl. Acad. Sci. U.S.A.* 115, 7099–7104. doi: 10.1073/pnas.1802165115
- Fu, L., Niu, B., Zhu, Z., Wu, S., and Li, W. (2012). CD-HIT: accelerated for clustering the next-generation sequencing data. *Bioinformatics* 28, 3150–3152. doi: 10.1093/bioinformatics/bts565
- Gales, A. C., Seifert, H., Gur, D., Castanheira, M., Jones, R. N., and Sader, H. S. (2019). Antimicrobial Susceptibility of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* Complex and *Stenotrophomonas maltophilia* Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program, (1997–2016). *Open Forum Infect. Dis.* 6, S34–S46. doi: 10.1093/ofid/ofy293
- Gautam, V., Patil, P. P., Bansal, K., Kumar, S., Kaur, A., Singh, A., et al. (2021). Description of *Stenotrophomonas sepilia* sp. nov., isolated from blood culture of a hospitalized patient as a new member of *Stenotrophomonas maltophilia* complex. *New Microbes New Infect.* 43, 100920. doi: 10.1016/j.nmni.2021.100920
- Gil-Gil, T., Martínez, J. L., and Blanco, P. (2020). Mechanisms of antimicrobial resistance in *Stenotrophomonas maltophilia*: a review of current knowledge. *Expert Rev. Anti-infective Ther.* 18, 335–347. doi: 10.1080/14787210.2020.1730178
- Gröschel, M. I., Meehan, C. J., Barilar, I., Diricks, M., Gonzaga, A., Steglich, M., et al. (2020). The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist *Stenotrophomonas maltophilia*. *Nat. Commun.* 11, 2044. doi: 10.1038/s41467-020-15123-0
- Gurevich, A., Saveliev, V., Vyahhi, N., and Tesler, G. (2013). QUAST: quality assessment tool for genome assemblies. *Bioinformatics* 29, 1072–1075. doi: 10.1093/bioinformatics/btt086
- Huang, Z., Yu, K., Fu, S., Xiao, Y., Wei, Q., and Wang, D. (2022). Genomic analysis reveals high intra-species diversity of *Shewanella* algae. *Microb. Genom.* 8, 000786. doi: 10.1099/mgen.0.000786
- Isom, C. M., Fort, B., and Anderson, G. G. (2022). Evaluating metabolic pathways and biofilm formation in *Stenotrophomonas maltophilia*. *J. Bacteriol.* 204, e0039821. doi: 10.1128/JB.00398-21
- Jain, C., Rodriguez-R, L. M., Phillippy, A. M., Konstantinidis, K. T., and Aluru, S. (2018). High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nat. Commun.* 9, 5114. doi: 10.1038/s41467-018-07641-9
- Kazmierczak, B. L., Schniederberend, M., and Jain, R. (2015). Cross-regulation of *Pseudomonas* motility systems: the intimate relationship between flagella, pili and virulence. *Curr. Opin. Microbiol.* 28, 78–82. doi: 10.1016/j.mib.2015.07.017
- Kumar, S., Bansal, K., Patil, P. P., Kaur, A., Kaur, S., Jaswal, V., et al. (2020). Genomic insights into evolution of extensive drug resistance in *Stenotrophomonas maltophilia* complex. *Genomics* 112, 4171–4178. doi: 10.1016/j.ygeno.2020.06.049
- Lee, D.-H., Cha, J.-H., Kim, D.-W., Lee, K., Kim, Y.-S., Oh, H.-Y., et al. (2022). Colistin-degrading proteases confer collective resistance to microbial communities during polymicrobial infections. *Microbiome* 10, 129. doi: 10.1186/s40168-022-01315-x
- Li, Y., Zhao, A., Yu, Q., Yu, N., Cui, Y., Ma, X., et al. (2023). Effect of *Stenotrophomonas maltophilia* on tuberculosis. *Microbiol. Spectr.* 11, e0094423. doi: 10.1128/spectrum.00944-23
- Li, Z., Lu, X., Wang, D., Liang, W. L., Zhang, J., Li, J., et al. (2019). Genomic comparison of serogroups O159 and O170 with other *Vibrio cholerae* serogroups. *BMC Genomics* 20, 241. doi: 10.1186/s12864-019-5603-7
- Lira, F., Berg, G., and Martínez, J. L. (2017). Double-face meets the bacterial world: the opportunistic pathogen *Stenotrophomonas maltophilia*. *Front. Microbiol.* 8, 2019. doi: 10.3389/fmicb.2017.02190
- Liu, B., Zheng, D., Zhou, S., Chen, L., and Yang, J. (2022). VFDB 2022: a general classification scheme for bacterial virulence factors. *Nucleic Acids Res.* 50, D912–D917. doi: 10.1093/nar/gkab1107
- Mercier-Darty, M., Royer, G., Lamy, B., Charron, C., Lemenand, O., Gomart, C., et al. (2020). Comparative whole-genome phylogeny of animal, environmental, and human strains confirms the genogroup organization and diversity of the *Stenotrophomonas maltophilia* complex. *Appl. Environ. Microbiol.* 86, e02919–e02919. doi: 10.1128/AEM.02919-19
- Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., et al. (2020). IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. *Mol. Biol. Evol.* 37, 1530–1534. doi: 10.1093/molbev/msaa015
- Mulcahy, L. R., Isabella, V. M., and Lewis, K. (2014). *Pseudomonas aeruginosa* biofilms in disease. *Microb. Ecol.* 68, 1–12. doi: 10.1007/s00248-013-0297-x
- Nieto, V., Kroken, A. R., Grosser, M. R., Smith, B. E., Metruccio, M. M. E., Hagan, P., et al. (2019). Type IV Pili can mediate bacterial motility within epithelial cells. *mBio* 10, e02880–e02818. doi: 10.1128/mBio.02880-18
- Ochoa-Sánchez, L. E., and Vinuesa, P. (2017). Evolutionary genetic analysis uncovers multiple species with distinct habitat preferences and antibiotic resistance phenotypes in the *Stenotrophomonas maltophilia* complex. *Front. Microbiol.* 8, 2017.01548. doi: 10.3389/fmicb.2017.01548
- Page, A. J., Cummins, C. A., Hunt, M., Wong, V. K., Reuter, S., Holden, M. T. G., et al. (2015). Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 31, 3691–3693. doi: 10.1093/bioinformatics/btv421
- Palleroni, N. J., and Bradbury, J. F. (1993). *Stenotrophomonas*, a new bacterial genus for *Xanthomonas maltophilia* (Hugh 1980) Swings et al. 1983. *Int. J. Syst. Bacteriol.* 43, 606–609. doi: 10.1099/00207173-43-3-606
- Patil, P. P., Kumar, S., Midha, S., Gautam, V., and Patil, P. B. (2018). Taxonogenomics reveal multiple novel genomospecies associated with clinical isolates of *Stenotrophomonas maltophilia*. *Front. Microbiol.* 7, 309. doi: 10.1099/mgen.0.000207
- Patil, P. P., Midha, S., Kumar, S., and Patil, P. B. (2016). Genome sequence of type strains of genus *Stenotrophomonas*. *Front. Microbiol.* 7, 309. doi: 10.3389/fmicb.2016.00309
- Pompilio, A., Piccolomini, R., Picciani, C., D'Antonio, D., Savini, V., and Di Bonaventura, G. (2008). Factors associated with adherence to and biofilm formation on polystyrene by *Stenotrophomonas maltophilia*: the role of cell surface hydrophobicity and motility. *FEMS Microbiol. Lett.* 287, 41–47. doi: 10.1111/j.1574-6968.2008.01292.x
- Pompilio, A., Ranalli, M., Piccirilli, A., Perilli, M., Vukovic, D., Savic, B., et al. (2020). Biofilm Formation among *Stenotrophomonas maltophilia* Isolates Has Clinical Relevance: The ANSELM Prospective Multicenter Study. *Microorganisms* 9, 49. doi: 10.3390/microorganisms9010049
- Rhee, J.-Y., Choi, J. Y., Choi, M.-J., Song, J.-H., Peck, K. R., and Ko, K. S. (2013). Distinct groups and antimicrobial resistance of clinical *Stenotrophomonas maltophilia* complex isolates from Korea. *J. Med. Microbiol.* 62, 748–753. doi: 10.1099/jmm.0.053355-0
- Sana, T. G., Flaugnatti, N., Lugo, K. A., Lam, L. H., Jacobson, A., Baylot, V., et al. (2016). *Salmonella* Typhimurium utilizes a T6SS-mediated antibacterial weapon to establish in the host gut. *Proc. Natl. Acad. Sci. U.S.A.* 113, E5044–E5051. doi: 10.1073/pnas.1608858113
- Sánchez, M. B., and Martínez, J. L. (2015). The efflux pump *smeDEF* contributes to trimethoprim-sulfamethoxazole resistance in *Stenotrophomonas maltophilia*. *Antimicrob. Agents Chemother.* 59, 4347–4348. doi: 10.1128/AAC.00714-15
- Seemann, T. (2014). Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068–2069. doi: 10.1093/bioinformatics/btu153
- Singh, A., Kumar, S., Bansal, K., and Patil, P. B. (2023). Taxonomic and phylogenomic assessment identifies phyto-pathogenicity potential of *Stenotrophomonas maltophilia* complex. *Phytopathology* 113, 1833–1838. doi: 10.1094/PHYTO-11-22-0434-SC
- Soto, S. M., Smithson, A., Martínez, J. A., Horcajada, J. P., Mensa, J., and Vila, J. (2007). Biofilm formation in uropathogenic *Escherichia coli* strains: relationship with prostatitis, uroviremia factors and antimicrobial resistance. *J. Urol.* 177, 365–368. doi: 10.1016/j.juro.2006.08.081
- Sun, E., Liang, G., Wang, L., Wei, W., Lei, M., Song, S., et al. (2016). Antimicrobial susceptibility of hospital acquired *Stenotrophomonas maltophilia* isolate biofilms. *Braz. J. Infect. Dis.* 20, 365–373. doi: 10.1016/j.bjid.2016.04.002
- Wang, Y., He, T., Shen, Z., and Wu, C. (2018). Antimicrobial resistance in *Stenotrophomonas* spp. *Microbiol. Spectr.* 6, 6.1.04. doi: 10.1128/microbiolspec.ARBA-0005-2017
- Wang, X., Zhao, J., Ji, F., Chang, H., Qin, J., Zhang, C., et al. (2021). Multiple-replicon resistance plasmids of *Klebsiella* mediate extensive dissemination of antimicrobial genes. *Front. Microbiol.* 12, 2021.754931. doi: 10.3389/fmicb.2021.754931
- Waters, V., Atenafu, E. G., Lu, A., Yau, Y., Tullis, E., and Ratjen, F. (2013). Chronic *Stenotrophomonas maltophilia* infection and mortality or lung transplantation in cystic fibrosis patients. *J. Cyst Fibros* 12, 482–486. doi: 10.1016/j.jcf.2012.12.006
- Waters, V., Yau, Y., Prasad, S., Lu, A., Atenafu, E., Crandall, I., et al. (2011). *Stenotrophomonas maltophilia* in cystic fibrosis: serologic response and effect on lung disease. *Am. J. Respir. Crit. Care Med.* 183, 635–640. doi: 10.1164/rccm.201009-1392OC
- Xie, J., Chen, Y., Cai, G., Cai, R., Hu, Z., and Wang, H. (2023). Tree Visualization by One Table (tvBOT): a web application for visualizing, modifying and annotating phylogenetic trees. *Nucleic Acids Res.* 51, W587–W592. doi: 10.1093/nar/gkad359
- Zegadło, K., Gierón, M., Żarnowiec, P., Durlak-Popińska, K., Kręcis, B., Kaca, W., et al. (2023). Bacterial motility and its role in skin and wound infections. *Int. J. Mol. Sci.* 24, 1707. doi: 10.3390/ijms24021707
- Zhao, J., Liu, Y., Liu, Y., Wang, D., Ni, W., Wang, R., et al. (2018). Frequency and genetic determinants of tigecycline resistance in clinically isolated *Stenotrophomonas maltophilia* in Beijing, China. *Front. Microbiol.* 9, 2018.00549. doi: 10.3389/fmicb.2018.00549